Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics

Area of Science:

• Pharmacology
• Drug Interactions
• Clinical Pharmacology

Background:

• Fluvoxamine is known to inhibit cytochrome P450 1A2 (CYP1A2).
• This inhibition can impair the metabolism of other drugs, such as caffeine.
• The clinical significance of the interaction between fluvoxamine and caffeine requires further investigation.

Purpose of the Study:

• To investigate the pharmacokinetic and pharmacodynamic effects of fluvoxamine on caffeine.
• To evaluate how fluvoxamine influences caffeine's absorption, distribution, metabolism, and excretion.
• To assess the impact of this interaction on caffeine's central nervous system effects.

Main Methods:

• A double-blind, four-way crossover study was conducted with seven healthy participants.
• Participants received single doses of caffeine (250 mg) with either fluvoxamine or placebo.
• Plasma concentrations of caffeine and fluvoxamine were measured over 24 hours, alongside assessments of psychomotor performance, sedation, and EEG beta activity.

Main Results:

• Fluvoxamine significantly reduced the apparent oral clearance of caffeine by approximately 90%.
• The elimination half-life of caffeine was substantially prolonged from 4.9 to 56 hours in the presence of fluvoxamine.
• Despite the altered caffeine kinetics, fluvoxamine did not augment caffeine's stimulant effects on psychomotor performance, alertness, or EEG.

Conclusions:

• Fluvoxamine markedly impairs caffeine clearance and prolongs its half-life.
• No significant changes in caffeine's pharmacodynamic effects were observed.
• Potential adverse effects from caffeine accumulation with daily use in patients taking fluvoxamine cannot be ruled out.